Rationale for the design of combination therapies that are active in T-cell
lymphomas?
W. Plunkett
Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, Tx, USA
The lymphomas are the most diverse group of diseases within any single class of malignancy. More than thirty different clinico-pathologic diseases have been identified and classified. Such a variety of diseases of the lymphoid system likely are the result of the unique etiology of each individual tumor type. On the basis of function, T-cells and B-cells have distinctly different functions, and undoubtedly activate genes to drive the different specialized pathways to achieve these purposes. Factors that clearly have a role in lymphomagenesis include illegitimate gene recombination, infection by oncogenic viruses, impaired host immunity, and persistent proliferation driven by inflammation.
[>Read full article in PDF]